皮兹奇瓦 (ustekinumab-ttwe):一种用于治疗牛皮的新生物类似药
Bianca Lindecker1, Christopher Giuliano1, Pramodini B Kale-Pradhan1
1Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA.
The Annals of pharmacotherapy
|November 14, 2025
概括
Ustekinumab-ttwe是一种生物类似药,相当于 ustekinumab,用于中度至重度的斑块性牛皮. 这项分析证实了其可比的药理学,疗效和安全性,提供了新的治疗选择.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 斑块性牛皮是一种慢性炎症性皮肤疾病.
- 像乌斯特基努马布这样的生物药物提供了有针对性的治疗选择.
- 生物类似药的发展为参考生物制剂提供了替代品.
研究的目的:
- 评估乌斯特基努马布-特维的药理学,疗效和安全性.
- 确定乌斯特基努马布-特韦作为斑块性牛皮的生物类似药的治疗作用.
主要方法:
- 在PubMed,Embase和ClinicalTrials.gov.gov的系统文献搜索.
- 包括有关药理学,药理动力学,疗效,安全性和免疫性研究.
- 对药理动力学和III期临床试验数据的分析,比较乌斯特基努马布-ttwe和乌斯特基努马布.
主要成果:
- 乌斯特基努马布-ttwe的药理动力学参数与参考乌斯特基努马布相似.
- 第三阶段试验显示了相似的疗效,PASI得分变化为ustekinumab-ttwe的85.7%,ustekinumab.ttwe的86.4%.
- 乌斯特基努马布-TTWE证明了与乌斯特基努马布的药理学,药理动力学,疗效,安全性和免疫性等同.
结论:
- Ustekinumab-ttwe是一种相当于ustekinumab的生物类似药.
- 这为中度至严重的斑块性牛皮提供了额外的治疗选择.
- 与其他乌斯特基努马布生物类似药的进一步比较研究尚未提供.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
Bioequivalence studies: Biowaivers
211
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
211
Bioequivalence: Overview
1.7K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


